Source:http://linkedlifedata.com/resource/pubmed/id/10395845
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-9-7
|
| pubmed:abstractText |
Antiretroviral therapy commenced during primary human immunodeficiency virus type 1 (HIV-1) infection (PHI) may limit the extent of viral replication and prevent early loss of HIV-specific CD4 lymphocyte function. We studied the effect of current standard therapy (2 nucleoside analogues and a protease inhibitor) in 16 patients with symptomatic PHI. In the 13 patients who completed 1 year of treatment, plasma HIV RNA was <50 copies/mL and median CD4 cell counts were comparable to HIV-uninfected controls, with naive (CD45RA+CD62L+), primed (CD45RO+), and T cell receptor Vbeta subsets all within normal ranges. However, HIV-1 DNA levels in treated and untreated PHI patients were similar. Furthermore, CD8 cell counts remained elevated, including activated (CD38+HLA-DR+), replicating (Ki-67+), and cytotoxic (perforin+CD28-) lymphocytes. In conclusion, early antiretroviral therapy resulted in clearance of viremia and prevented loss of crucial CD4 subsets. The persistence of HIV-1 DNA together with increased CD8 T lymphocyte turnover and activation indicate continued expression of viral antigens.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Indinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0022-1899
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
180
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
320-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10395845-Adult,
pubmed-meshheading:10395845-Anti-HIV Agents,
pubmed-meshheading:10395845-CD4-Positive T-Lymphocytes,
pubmed-meshheading:10395845-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10395845-Cohort Studies,
pubmed-meshheading:10395845-DNA, Viral,
pubmed-meshheading:10395845-Drug Therapy, Combination,
pubmed-meshheading:10395845-HIV Antibodies,
pubmed-meshheading:10395845-HIV Infections,
pubmed-meshheading:10395845-HIV-1,
pubmed-meshheading:10395845-Humans,
pubmed-meshheading:10395845-Indinavir,
pubmed-meshheading:10395845-Lamivudine,
pubmed-meshheading:10395845-Leukocytes, Mononuclear,
pubmed-meshheading:10395845-Lymphocyte Activation,
pubmed-meshheading:10395845-Male,
pubmed-meshheading:10395845-Prospective Studies,
pubmed-meshheading:10395845-RNA, Viral,
pubmed-meshheading:10395845-T-Lymphocyte Subsets,
pubmed-meshheading:10395845-Viremia,
pubmed-meshheading:10395845-Zidovudine
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
|
| pubmed:affiliation |
Centre for Immunology, St. Vincent's Hospital, UNSW, Darlinghurst, Australia 2010 Australia. J.Zaunders@cfi.unsw.edu.au
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|